Publication:
A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia

dc.contributor.authorGemici, Aliihsan
dc.contributor.authorDogu, Mehmet Hilmi
dc.contributor.authorTekinalp, Atakan
dc.contributor.authorAlacacioglu, Inci
dc.contributor.authorGuney, Tekin
dc.contributor.authorInce, Idris
dc.contributor.authorGeduk, Ayfer
dc.contributor.authorCağlıyan, Gulsum Akgun
dc.contributor.authorMaral, Senem
dc.contributor.authorSerin, Istemi
dc.contributor.authorGunduz, Eren
dc.contributor.authorKarakus, Volkan
dc.contributor.authorBekoz, Huseyin Saffet
dc.contributor.authorEren, Rafet
dc.contributor.authorGunes, Ahmet Kursad
dc.contributor.authorSargin, Fatma Deniz
dc.contributor.authorSevindik, Omur Gokmen
dc.contributor.buuauthorOzkalemkas, Fahir
dc.contributor.buuauthorÖZKALEMKAŞ, FAHİR
dc.contributor.buuauthorPinar, Ibrahim Ethem
dc.contributor.buuauthorPINAR, İBRAHİM ETHEM
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.
dc.contributor.researcheridJWP-2738-2024
dc.contributor.researcheridAAA-5330-2022
dc.date.accessioned2024-06-12T10:31:37Z
dc.date.available2024-06-12T10:31:37Z
dc.date.issued2021-08-10
dc.description.abstractVenetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients with a median age of 67 years from different centers were included in the final analysis. Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML. Materials and Methods: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML. Results: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported. Conclusion: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML. (C) 2021 Elsevier Inc. All rights reserved.
dc.identifier.doi10.1016/j.clml.2021.04.004
dc.identifier.endpageE692
dc.identifier.issn2152-2650
dc.identifier.issue8
dc.identifier.startpageE686
dc.identifier.urihttps://doi.org/10.1016/j.clml.2021.04.004
dc.identifier.urihttps://hdl.handle.net/11452/42062
dc.identifier.volume21
dc.identifier.wos000684596500017
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherCig Media Group
dc.relation.journalClinical Lymphoma Myeloma & Leukemia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectLow-dose cytarabine
dc.subjectOlder patients
dc.subjectBcl-2 inhibition
dc.subjectAzacitidine
dc.subjectSurvival
dc.subjectCare
dc.subjectAml
dc.subjectBcl2
dc.subjectInhibitor
dc.subjectVenetoclax
dc.subjectAcute myeloid leukemia
dc.subjectReal life
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectOncology
dc.subjectHematology
dc.subjectOncology
dc.subjectHematology
dc.titleA real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication6d4676a2-f825-4560-bfa8-c7eb6daf748d
relation.isAuthorOfPublication780690ec-9c57-47ed-a462-d5d676cd36e3
relation.isAuthorOfPublication.latestForDiscovery6d4676a2-f825-4560-bfa8-c7eb6daf748d

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Özkalemtaş_vd_2021.pdf
Size:
588.32 KB
Format:
Adobe Portable Document Format

Collections